The recent expanded FDA label indication for Wegovy is the first of many potential new indications for GLP-1 drugs in the chronic weight management category. With more research in the pipeline that could show additional medical benefits for selected patient populations, employers now face more decisions about coverage related to GLP-1 drugs.
This guide covers:
- The patient population that qualifies for the expanded use of Wegovy
- An overview of clinical trials studying cardiovascular risk reduction in GLP-1s
- A comparison of PA criteria to consider for expanded use of Wegovy
